Kalyan Roy: How Platelet-Rich Plasma Accelerates Tissue Repair and Regeneration
Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:
”Platelet-Rich Plasma (PRP): Harnessing the Body’s Own Healing Power
Regenerative medicine is transforming healthcare, and Platelet-Rich Plasma (PRP) has emerged as one of its most promising biologic therapies.
Unlike conventional treatments that primarily relieve symptoms, PRP promotes tissue repair by utilizing the patient’s own platelets, concentrated to 3–8 times their normal level.
These platelets release a rich cocktail of growth factors and cytokines that stimulate healing, angiogenesis, collagen synthesis, stem cell recruitment, and modulation of inflammation.
Key Growth Factors in PRP
- PDGF – Cell proliferation and tissue repair
- TGF-β – Collagen synthesis and cartilage healing
- VEGF – Angiogenesis and vascular regeneration
- EGF – Skin and epithelial repair
- IGF-1 – Muscle and bone regeneration
- FGF – Fibroblast activation and tendon healing
Clinical Applications
- Knee Osteoarthritis
- Chronic Tendinopathies (Tennis Elbow, Achilles Tendinopathy)
- Sports Injuries
- Androgenetic Alopecia (Hair Restoration)
- Chronic Non-healing Wounds
- Oral and Maxillofacial Surgery
- Plastic Surgery and Skin Rejuvenation
How Does PRP Work?
Hemostasis, followed by Controlled Inflammation, followed by Cellular Proliferation, and finally Tissue Remodeling
Current Evidence
The strongest scientific evidence supports PRP in mild-to-moderate knee osteoarthritis, chronic tendinopathies, and androgenetic alopecia. While outcomes are encouraging, standardized preparation protocols and high-quality clinical trials remain essential to optimize its therapeutic potential.
PRP is not simply a platelet concentrate—it represents a shift toward biologic, personalized, and regenerative medicine, where the patient’s own blood becomes a powerful tool for healing.
Stay updated with Hemostasis Today.
-
Sep 4, 2026, 21:54Gianluca Costamagna: Investigating the Link Between Cancer and Acute Ischemic Stroke
-
Sep 4, 2026, 21:50Ben Creagh-Brown: PRAGUE-26 and HI-PEITHO Similar Benefits With Important Differences
-
Sep 4, 2026, 21:48Jin-Xiong She: Homocysteine beyond Heart Disease – The Methylation-Mobility Connection
-
Sep 4, 2026, 21:44Aravind Palraj: Anemia of Chronic Inflammation is Not Just “Iron Deficiency”
-
Sep 4, 2026, 21:41Chokri Ben Lamine: Fundamental HSCT Workshop for Hematology Fellows at HAAG 2026
-
Sep 4, 2026, 21:39Pierre Sabouret: A Good Surprise Our New Publication in Life Is Online
-
Sep 4, 2026, 21:37Maria Queralt Gorgas: Treating AF With Intermediate Stroke Risk With Anticoagulation
-
Sep 4, 2026, 18:49Børge Nordestgaard: Lp(a) Remains a Risk Factor Across the Lifespan
-
Sep 4, 2026, 18:22Tareq Abadl: The Clinical Meaning of C3 and C4